{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:50:56Z","timestamp":1759812656299},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Youth Foundation of the First Affiliated Hospital of Zhengzhou University"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.mehy.2013.07.047","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T04:16:01Z","timestamp":1376367361000},"page":"892-895","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HMGB1: A potential target for treatment of benign prostatic hyperplasia"],"prefix":"10.1016","volume":"81","author":[{"given":"Xue","family":"Rui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma","family":"Shengli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhankui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi","family":"Guofu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jinjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2013.07.047_b0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","article-title":"High prevalence of benign prostatic hypertrophy in the community","volume":"338","author":"Garraway","year":"1991","journal-title":"Lancet"},{"issue":"Suppl. 9","key":"10.1016\/j.mehy.2013.07.047_b0010","first-page":"S3","article-title":"Benign prostatic hyperplasia: an overview","volume":"7","author":"Roehrborn","year":"2005","journal-title":"Rev Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOU.0b013e32834d8e87","article-title":"American urological association and European association of urology guidelines in the management of benign prostatic hypertrophy: revisited","volume":"22","author":"Juliao","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-5347(17)71941-6","article-title":"Inflammation of the prostate gland","volume":"38","author":"Moore","year":"1937","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2007.09.012","article-title":"Inflammation and benign prostatic hyperplasia","volume":"35","author":"Nickel","year":"2008","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.mehy.2013.07.047_b0030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","article-title":"Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?","volume":"51","author":"Kramer","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0035","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.eururo.2007.06.038","article-title":"Inflammation and chronic prostatic diseases: evidence for a link?","volume":"52","author":"Sciarra","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1464-410X.2007.06910.x","article-title":"Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?","volume":"100","author":"Mishra","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.mehy.2013.07.047_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.mou.0000193368.91823.1b","article-title":"Could inflammation be a key component in the progression of benign prostatic hyperplasia?","volume":"16","author":"Kramer","year":"2006","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0305","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.urology.2007.11.155","article-title":"Longitudinal association between prostatitis and development of benign prostatic hyperplasia","volume":"71","author":"St. Sauver","year":"2008","journal-title":"Urology"},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2013.07.047_b0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2006.06098.x","article-title":"Definition of at-risk patients: baseline variables","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.mehy.2013.07.047_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pros.10084","article-title":"Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation","volume":"52","author":"Kramer","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.mehy.2013.07.047_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","article-title":"Expressionand function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate","volume":"56","author":"Steiner","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.mehy.2013.07.047_b0070","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.LAB.0000081388.40145.65","article-title":"Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue","volume":"83","author":"Steiner","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.mehy.2013.07.047_b0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0968-0004(00)01777-1","article-title":"Revised nomenclature for high mobility group (HMG) chromosomal proteins","volume":"26","author":"Bustin","year":"2001","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.mehy.2013.07.047_b0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-4781(90)90092-G","article-title":"Structural features of the HMG chromosomal proteins and their genes","volume":"1049","author":"Bustin","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2013.07.047_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1432-1033.1989.tb15116.x","article-title":"Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions","volume":"185","author":"Mosevitsky","year":"1989","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.mehy.2013.07.047_b0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/geno.1998.5214","article-title":"Hmg4, a new member of the Hmg1\/2 gene family","volume":"49","author":"Vaccari","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.mehy.2013.07.047_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbaexp.2003.10.017","article-title":"Chromatin and cell death","volume":"1677","author":"Bianchi","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2013.07.047_b0100","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1083\/jcb.152.6.1197","article-title":"The high mobility group (HMG) boxes of the nuclear protein HMG1induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells","volume":"152","author":"Degryse","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.mehy.2013.07.047_b0105","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1182\/blood-2002-05-1300","article-title":"Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells","volume":"101","author":"Fiuza","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.07.047_b0110","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/00003246-200301001-00007","article-title":"Targeting high mobility group box 1 as a lateacting mediator of inflammation","volume":"31","author":"Czura","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.mehy.2013.07.047_b0120","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1164\/ajrccm.164.10.2106117","article-title":"HMGB1 as a late mediator of lethal systemic inflammation","volume":"164","author":"Wang","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mehy.2013.07.047_b0125","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.4049\/jimmunol.165.6.2950","article-title":"Cutting edge: HMG-1 as a mediator of acute lung inflammation","volume":"165","author":"Abraham","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2013.07.047_b0130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0140-6736(99)02658-6","article-title":"Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock","volume":"354","author":"Ombrellino","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2013.07.047_b0135","doi-asserted-by":"crossref","first-page":"19919","DOI":"10.1074\/jbc.274.28.19919","article-title":"Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor butdifferent downstream signaling pathways","volume":"274","author":"Huttunen","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2013.07.047_b0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2796.2003.01204.x","article-title":"High mobility group 1 B-box mediates activation of human endothelium","volume":"254","author":"Treutiger","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0039-6060(99)70182-0","article-title":"Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes","volume":"126","author":"Wang","year":"1999","journal-title":"Surgery"},{"key":"10.1016\/j.mehy.2013.07.047_b0150","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.imbio.2009.11.001","article-title":"HMGB1 activates nuclear factor-kappaB signaling by RAGE and increases the production of TNF-alpha in human umbilical vein endothelial cells","volume":"215","author":"Luan","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.mehy.2013.07.047_b0155","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0022-5347(05)65301-3","article-title":"Prevalence and correlates of prostatitis in the health professionals follow-up study cohort","volume":"167","author":"Collins","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2013.07.047_b0160","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","article-title":"The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial","volume":"54","author":"Nickel","year":"2008","journal-title":"Eur Urol"},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2013.07.047_b0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2006.06098.x","article-title":"Definition of at-risk patients: baseline variables","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.mehy.2013.07.047_b0170","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/pros.21027","article-title":"Inflammation in benign prostatic hyperplasia: a 282 patients\u2019 immunohistochemical analysis","volume":"69","author":"Robert","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.mehy.2013.07.047_b0175","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/pros.21433","article-title":"Acute bacterial inflammation of the mouse prostate","volume":"72","author":"Boehm","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.mehy.2013.07.047_b0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/pros.20051","article-title":"Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia","volume":"60","author":"Castro","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.mehy.2013.07.047_b0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ucl.2009.07.003","article-title":"Etiology, epidemiology, and natural history of benign prostatic hyperplasia","volume":"36","author":"Bushman","year":"2009","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.mehy.2013.07.047_b0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"HMGB-1 stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/bj3200253","article-title":"Extracellular high-mobility group 1 protein is essential for murine erythroleukaemia cell differentiation","volume":"320","author":"Sparatore","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.mehy.2013.07.047_b0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2013.07.047_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.1104648","article-title":"The cytokine activity of HMGB1","volume":"78","author":"Yang","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.mehy.2013.07.047_b0210","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.20052203","article-title":"Role of HMGB1 in apoptosis-mediated sepsis lethality","volume":"203","author":"Qin","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/ncprheum0379","article-title":"Mechanisms of disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis","volume":"3","author":"Jiang","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.mehy.2013.07.047_b0315","doi-asserted-by":"crossref","first-page":"C1318","DOI":"10.1152\/ajpcell.00616.2005","article-title":"The extracellular release ofHMGB1 during apoptotic cell death","volume":"291","author":"Bell","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.mehy.2013.07.047_b0225","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.173.1.307","article-title":"High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization","volume":"173","author":"Messmer","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2013.07.047_b0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0306180","article-title":"High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin","volume":"81","author":"Yang","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.mehy.2013.07.047_b0235","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.4049\/jimmunol.174.12.7506","article-title":"Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products","volume":"174","author":"Dumitriu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2013.07.047_b0240","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.0306200","article-title":"Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin)","volume":"81","author":"Rouhiainen","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.mehy.2013.07.047_b0250","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.emboj.7601552","article-title":"A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin","volume":"26","author":"Orlova","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.mehy.2013.07.047_b0255","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.11161","article-title":"Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity","volume":"48","author":"Kokkola","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2013.07.047_b0260","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.23729","article-title":"Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis","volume":"58","author":"Hamada","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2013.07.047_b0265","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20042614","article-title":"The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion","volume":"201","author":"Tsung","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187221412802481784","article-title":"HMGB-1 as a target for inflammation controlling","volume":"6","author":"Nogueira-Machadoa","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.mehy.2013.07.047_b0275","doi-asserted-by":"crossref","first-page":"157103","DOI":"10.1155\/2013\/157103","article-title":"HMGB1: a promising therapeutic target for prostate cancer","volume":"2013","author":"Gnanasekar","year":"2013","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.mehy.2013.07.047_b0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.20070679","article-title":"RAGE signaling sustains inflammation and promotes tumor development","volume":"205","author":"Gebhardt","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2013.07.047_b0285","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2013.07.047_b0325","doi-asserted-by":"crossref","first-page":"19845","DOI":"10.1371\/journal.pone.0019845","article-title":"HMGB1 attenuates cardiac remodeling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3","volume":"6e","author":"Limana","year":"2011","journal-title":"Plos One"},{"key":"10.1016\/j.mehy.2013.07.047_b0295","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.autrev.2012.03.007","article-title":"HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis","volume":"11","author":"de Souza","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.mehy.2013.07.047_b0330","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB1 in cancer: good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771300371X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771300371X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T17:06:01Z","timestamp":1646327161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030698771300371X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S030698771300371X"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2013.07.047","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HMGB1: A potential target for treatment of benign prostatic hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2013.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}